chr2-47799328-C-T
Variant summary
Our verdict is Benign. Variant got -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBS1BS2
The NM_000179.3(MSH6):c.1345C>T(p.Leu449Leu) variant causes a synonymous change. The variant allele was found at a frequency of 0.000809 in 1,613,886 control chromosomes in the GnomAD database, including 11 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Consequence
NM_000179.3 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00389 AC: 591AN: 152094Hom.: 6 Cov.: 32
GnomAD3 exomes AF: 0.00106 AC: 265AN: 251026Hom.: 1 AF XY: 0.000722 AC XY: 98AN XY: 135688
GnomAD4 exome AF: 0.000485 AC: 709AN: 1461674Hom.: 5 Cov.: 34 AF XY: 0.000430 AC XY: 313AN XY: 727150
GnomAD4 genome AF: 0.00392 AC: 596AN: 152212Hom.: 6 Cov.: 32 AF XY: 0.00352 AC XY: 262AN XY: 74428
ClinVar
Submissions by phenotype
not specified Benign:7
- -
- -
- -
- -
- -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
- -
not provided Benign:4
- -
- -
- -
- -
Hereditary cancer-predisposing syndrome Benign:3
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
The synonymous variant NM_000179.3(MSH6):c.1345C>T (p.Leu449=) has been reported to ClinVar as Benign with a status of (2 stars) criteria provided, multiple submitters, no conflicts (Variation ID 36583 as of 2025-01-02). The variant is observed in one or more wwhich is greater than expected for the disorder. The p.Leu449= variant is not predicted to disrupt an existing splice site. The p.Leu449= variant is predicted to introduce a novel splice site by 1 of 4 splice site algorithms. For these reasons, this variant has been classified as Benign. -
- -
Lynch syndrome 5 Benign:2
- -
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. -
Breast and/or ovarian cancer Benign:1
- -
Lynch syndrome Benign:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Malignant tumor of breast Benign:1
The MSH6 p.Leu449= variant was not identified in the literature. The variant was identified in dbSNP (ID: rs3136333) as "With Benign allele", ClinVar (classified as benign by Invitae, Ambry Genetics and six other submitters), and in UMD-LSDB (2x as neutral) database. The variant was identified in control databases in 351 of 276748 chromosomes (2 homozygous) at a frequency of 0.001, increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 341 of 24010 chromosomes (2 homozygous, freq: 0.01), Other in 1 of 6464 chromosomes (freq: 0.0002), Latino in 5 of 34396 chromosomes (freq: 0.0002), European in 3 of 126476 chromosomes (freq: 0.00002), and South Asian in 1 of 30782 chromosomes (freq: 0.00003), while the variant was not observed in the Ashkenazi Jewish, East Asian, or Finnish populations. The p.Leu449= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, 1 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predicts a greater that 10% difference in splicing. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at